Connect lipid metabolism and cardiovascular risk with lipid-lowering drug mechanisms, treatment selection, monitoring, and medication safety.
Course Content
01. Lipid-Lowering Drugs: Clinical Pharmacology Map
You don't currently have access to this content
02. Lipoprotein Metabolism and Drug Targets
You don't currently have access to this content
03. Risk Assessment, Biomarkers, and Treatment Goals
You don't currently have access to this content
04. Primary Dyslipidemia Phenotypes
You don't currently have access to this content
05. Clinical Clues and Secondary Causes
You don't currently have access to this content
06. Lifestyle Therapy: The Foundation
You don't currently have access to this content
07. Statins: Mechanism and Pleiotropic Effects
You don't currently have access to this content
08. Statin Intensity and Clinical Use
You don't currently have access to this content
09. Statin Pharmacokinetics and Drug Interactions
You don't currently have access to this content
10. Statin Adverse Effects, Monitoring, and Pregnancy
You don't currently have access to this content
11. Ezetimibe: Intestinal Cholesterol Absorption Blocker
You don't currently have access to this content
12. PCSK9 Monoclonal Antibodies
You don't currently have access to this content
13. Inclisiran: PCSK9 Gene Silencing
You don't currently have access to this content
14. Bempedoic Acid: ATP Citrate Lyase Inhibitor
You don't currently have access to this content
15. Bile Acid Sequestrants
You don't currently have access to this content
16. Fibrates: PPAR-Alpha Agonists
You don't currently have access to this content
17. Omega-3 Fatty Acids and Icosapent Ethyl
You don't currently have access to this content
18. Niacin: Strong HDL Effect, Limited Modern Role
You don't currently have access to this content
19. Severe Hypertriglyceridemia and ApoC-III Therapy
You don't currently have access to this content
20. Familial Hypercholesterolemia
You don't currently have access to this content
21. HoFH Specialty Therapies
You don't currently have access to this content
22. ApoB, Non-HDL-C, and Lipoprotein(a)
You don't currently have access to this content
23. Combination Therapy: Synergy by Mechanism
You don't currently have access to this content
24. LDL-Driven ASCVD Treatment Strategy
You don't currently have access to this content
25. Triglyceride-Driven Treatment Strategy
You don't currently have access to this content
26. Special Populations
You don't currently have access to this content
27. Monitoring, Counseling, and Red Flags
You don't currently have access to this content
28. Final Board-Ready Takeaways
You don't currently have access to this content